Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Diet,And,Dieting.,Beauty,Slim,Female,Body,Use,Tape,Measure.

On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

In the first study, nimacimab matched or exceeded the weight loss of Novo Nordisk's (NYSE:NVO) monlunabant while showing superior post-treatment maintenance.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.